Hepatic fibrosis: molecular mechanisms and drug targets

Area of Science:

• Hepatology
• Molecular Biology
• Drug Discovery

Background:

• Liver fibrosis is a common pathological response to chronic liver injury, potentially leading to cirrhosis, liver failure, and cancer.
• Current treatments for hepatic fibrosis are limited, primarily focusing on removing the causative agent, and effective antifibrotic drugs are scarce.
• While research has targeted fibrogenic cells, recent efforts also explore inhibiting parenchymal injury and reducing liver inflammation.

Purpose of the Study:

• To review recent advancements in understanding the molecular mechanisms driving liver fibrosis.
• To discuss emerging therapeutic strategies for liver fibrosis based on these mechanistic insights.
• To highlight the current landscape of antifibrotic drug development and clinical trials.

Main Methods:

• Literature review of recent studies on liver fibrosis.
• Analysis of molecular mechanisms underlying fibrogenesis and antifibrotic targets.
• Survey of preclinical and clinical trial data for antifibrotic agents.

Main Results:

• Significant progress has been made in elucidating the molecular pathways involved in liver fibrosis.
• Multiple antifibrotic strategies targeting fibrogenic cells, parenchymal injury, and inflammation have shown promise.
• Numerous molecules are in various stages of preclinical and clinical development, indicating a growing pipeline of potential therapies.

Conclusions:

• A deeper understanding of liver fibrosis mechanisms is paving the way for novel therapeutic interventions.
• Mechanistically-driven antifibrotic strategies represent a promising avenue for treating liver fibrosis.
• The ongoing development and clinical evaluation of new antifibrotic drugs offer hope for improved patient outcomes.